Nexvel Biotech Showcases Its Medical Aesthetics Expertise at Vietbeauty & Cosmobeauté Vietnam 2026, Accelerating Global Market Expansion

 

Nexvel Biotech, a leading medical aesthetics company, successfully participated in Vietbeauty & Cosmobeauté Vietnam 2026, held from July 23 to 25 at the Saigon Exhibition and Convention Center (SECC) in Ho Chi Minh City, Vietnam. Through the exhibition, the company strengthened its global presence and further expanded its business opportunities across the ASEAN region.

 

Vietbeauty & Cosmobeauté is one of Southeast Asia's largest B2B beauty exhibitions, bringing together global buyers, distributors, medical professionals, and beauty industry leaders every year. As the beauty industry increasingly converges with medical aesthetics and biotechnology, the exhibition has become an important platform for companies with advanced scientific and clinical expertise.

 

At the exhibition, Nexvel Biotech presented its flagship medical aesthetics portfolio, including Aeshilo™, Amethea PLLA™, Amethea PN™, Amethea SA™, and Amethea NAD™. The company's next-generation hyaluronic acid (HA)-based skin booster and PLLA-based collagen regeneration solutions attracted significant attention from international buyers seeking innovative, clinically driven aesthetic products.

 

Vietnam's medical aesthetics industry continues to grow rapidly, while the skin booster segment remains in its early stage of development. This presents promising opportunities for advanced technologies and premium treatment solutions. During the exhibition, Nexvel Biotech confirmed the strong market potential for Korean-made skin boosters and experienced growing demand for scientifically developed aesthetic products.

 

Throughout the three-day exhibition, the company held productive business meetings with buyers from Vietnam, India, Indonesia, the Philippines, the Middle East, and other international markets. Visitors expressed strong interest in Nexvel Biotech's differentiated technologies, manufacturing capabilities, product quality, and clinical development expertise, leading to active discussions on new distribution partnerships and market expansion.

 

In addition to its medical device portfolio, Nexvel Biotech also introduced DU2LAB, its premium cosmeceutical skincare brand developed from the company's skin booster technology. Built upon years of expertise in medical aesthetic research and development, DU2LAB demonstrated how advanced medical technologies can be translated into high-performance daily skincare solutions. This unique brand story resonated strongly with international buyers and highlighted a new direction where medical aesthetics and cosmetics converge.

 

A company representative commented, "This exhibition confirmed the growing global interest in Korean skin booster technology and medical aesthetics. We were especially encouraged by the positive response to Nexvel Biotech's R&D capabilities and technological expertise, which further strengthened our confidence in expanding into new international markets."

 

The representative added, "The valuable market insights and buyer feedback obtained during the exhibition will serve as an important foundation for our localization strategies and future global partnerships. Moving forward, we will continue to invest in research and innovation while expanding our international network to deliver advanced medical aesthetic solutions to customers worldwide."

 

With the global medical aesthetics market continuing to grow alongside increasing demand for skin rejuvenation, minimally invasive treatments, and science-based skincare, Nexvel Biotech is committed to strengthening its leadership in skin boosters and dermal fillers while expanding its integrated medical aesthetics and cosmeceutical business. The company aims to further establish the global reputation of Korean medical aesthetic technology through continuous innovation and long-term partnerships.